Literature DB >> 25820762

New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?

Aaron Liew1, Siavash Piran, James Douketis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25820762     DOI： 10.1007/s11739-015-1224-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  40 in total

1.  Newly identified events in the RE-LY trial.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; Paul A Reilly; Lars Wallentin
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

3.  The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.

Authors:  Matthew A Cavender; C Michael Gibson; Eugene Braunwald; Stephen D Wiviott; Sabina A Murphy; Eri Toda Kato; Alexei N Plotnikov; Marcos Amuchástegui; Ton Oude Ophuis; Maarten van Hessen; Jessica L Mega
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2014-10-15

4.  The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

Authors:  Linda E Lévesque; James M Brophy; Bin Zhang
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

5.  A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.

Authors:  Rui Providência; Erik Lerkevang Grove; Steen Husted; Sérgio Barra; Serge Boveda; João Morais
Journal:  Thromb Res       Date:  2014-10-13       Impact factor: 3.944

6.  Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

Authors:  Jonas Oldgren; Andrzej Budaj; Christopher B Granger; Yasser Khder; Juliet Roberts; Agneta Siegbahn; Jan G P Tijssen; Frans Van de Werf; Lars Wallentin
Journal:  Eur Heart J       Date:  2011-05-07       Impact factor: 29.983

7.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 8.  Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.

Authors:  Antonio Gómez-Outes; Ana Isabel Terleira-Fernández; Ramón Lecumberri; M Luisa Suárez-Gea; Emilio Vargas-Castrillón
Journal:  Thromb Res       Date:  2014-07-06       Impact factor: 3.944

9.  Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.

Authors:  Yoon K Loke; Shiva Pradhan; Jessica Ka-Yan Yeong; Chun Shing Kwok
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 10.  Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jonathan Douxfils; Fanny Buckinx; François Mullier; Valentine Minet; Véronique Rabenda; Jean-Yves Reginster; Philippe Hainaut; Olivier Bruyère; Jean-Michel Dogné
Journal:  J Am Heart Assoc       Date:  2014-06-06       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.